References
- Pearson DC, May GR, Fick GH, Sutherland LR. Azathioprine and 6-mercaptopurine in Crohn’s disease. A meta-analysis. Ann Intern Med 1995;123:132–42.
- Ewe K, Press AG, Singe CC, Singe CC, Stufler M, Ueberschaer B, et al. Azathioprine combined with prednisolone or monotherapy with prednisolone in active Crohn’s disease. Gastroenterology 1993;105:367–72.
- Korelitz BI, Adler DJ, Mendelsohn RA, Sacknoff AL. Longterm experience with 6-mercaptopurine in the treatment of Crohn’s disease. Am J Gastroenterol 1993;88:1198–205.
- Blondel-Kucharki F, Chircop C, Marquis P, Colombel JF, Gendre JP, et le GETAID. Qualité de vie au cours de la maladie de Crohn. Etude prospective longitudinale de 231 patients [abstract]. Gastroenterol Clin Biol 1999;23:A85.
- Sandborn WJ. Azathioprine: state of art in inflammatory bowel disease. Scand J Gastroenterol 1998;33 Suppl 225:92–9.
- Cuffari C, Théort Y, Latour S, Seidman G. 6-Mercaptopurine metabolism in Crohn’s disease: correlation with efficacy and toxicity. Gut 1996;39:401–6.
- Gower-Rousseau C, Salomez JL, Dupas JL, Marti R, Nuttens MC, Votte A, et al. Incidence of inflammatory bowel disease in northern France (1988–1990). Gut 1994;35: 1433–8.
- Franchimont D, Louis E, Croes F, Belaiche J. Clinical pattern of corticosteroid dependent Crohn’s disease. Eur J Gastroenterol Hepatol 1998;10:821–5.
- Lennard L, Singleton HJ. High-performance liquid chromatographic assay of the methyl and nucleotide metabolites of 6-mercaptopurine: quantitation of red blood cell 6-thioguanine nucleotide, 6-thioinosinic acid and 6-methylmercaptopurine metabolites in a single sample. J Chromatogr B Biomed Appl 1992;583:83–90.
- Dubinsky MC, Lamothe S, Yang HY, Targan SR, Sinnett D, Theort Y, et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 2000;118:705–13.
- Cuffari C, Picco M, Hunt S, Bayless T. Azathioprine metabolite levels predict clinical responsiveness to therapy in IBD [abstract]. Gastroenterology 1999;116:G3020.
- Barbe L, Marteau Ph, Lemann M, Bouhnik Y, Allez M, Coffin B, et al. Dose raising of azathioprine beyond 2.5 mg/kg/day in Crohn’s disease patients who fail to improve with a standard dose [abstract]. Gastroenterology 1998;114:G3794.
- Colonna T, Korelitz BI. The role of leukopenia in the 6-mercaptopurine-induced remission of refractory Crohn’s disease. Am J Gastroenterol 1994;89:362–6.
- Sandborn WJ, Tremaine WJ, Wolf DC, Targan SR, Sninski CA, Sutherland RS, et al. Lack of effect of intravenous administration on time to respond to azathioprine for steroid-treated Crohn’s disease. Gastroenterology 1999;117:527–35.
- Cattan S, Lémann M, Thuillier F, Bengoufa D, Rabian C, Ngo Y, et al. Dosage de la 6-mercaptopurine et etude des souspopulations lymphocytaires sanguines au cours du traitement par l’azathioprine dans la maladie de Crohn. Gastroenterol Clin Biol 1998;22:160–7.
- Lillemans JS, Lennard L. Mercaptopurine metabolism and risk of relapse in childhood lymphoblastic leukemia. Lancet 1994;343:1188–90.
- Lennard L, Lilleyman JS. Variable mercaptopurine metabolism and treatment outcome in childhood lymphoblastic leukemia. J Clin Oncol 1989;7:1816–23.
- Bergan S, Rugstad HE, Bentdal O, Sodal G, Hartmann A, Leivestad T, et al. Monitored high-dose azathioprine treatment reduce acute rejection episodes after renal transplantation. Transplantation 1998;66:334–9.
- Schutz E, Gummert J, Amstrong VW, Mohr FW, Oellerich M. Azathioprine pharmacogenetics: the relationship between 6-thioguanine nucleotides and thiopurine methyltransferase in patients after heart and kidney transplantation. Eur J Clin Chem Clin Biochem 1996;34: 199–205.
- Sandborn WJ. 6-MP metabolite levels: a potential guide to Crohn’s disease therapy. Gastroenterology 1997;113:690–2.
- Decaux G, Propert F, Horsmans Y, Desager JP. Relationship between red cell mean corpuscular volume and 6-thioguanine nucleotides in patients treated with azathioprine. J Lab Clin Med 2000;135:256–62.